Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company. The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares.
Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company.
The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares. Proceeds from the offering, to be made at $10 to$12 a share, will support ongoing R&D activities.
Sonus has completed phase II clinical testing of EchoGen, amicrobubble ultrasound contrast agent potentially useful in echocardiographyand perfusion procedures. It plans to file a new drug applicationwith the Food and Drug Administration by April 1, 1996.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.